File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.biopha.2023.115123
- Scopus: eid_2-s2.0-85164355898
- WOS: WOS:001029051100001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: IPSC-derived CAR-NK cells for cancer immunotherapy
| Title | IPSC-derived CAR-NK cells for cancer immunotherapy |
|---|---|
| Authors | |
| Keywords | Chimeric antigen receptor Immunotherpy Induced pluripotent stem cell Natural killer cell |
| Issue Date | 1-Sep-2023 |
| Publisher | Elsevier |
| Citation | Biomedicine and Pharmacotherapy, 2023, v. 165 How to Cite? |
| Abstract | Adoptive cell therapies (ACT) based on chimeric antigen receptor (CAR)-modified immune cells have made great progress with six CAR-T cell products approved by the U.S. FDA for hematological malignancies. Compared with CAR-T cells, CAR-NK cells have attracted increasing attention owing to their multiple killing mechanisms, higher safety profile, and broad sources. Induced pluripotent stem cell (iPSC)-derived NK (iPSC-NK) cells possess a mature phenotype and potent cytolytic activity, and can provide a homogeneous population of CAR-NK cells that can be expanded to clinical scale. Thus, iPSC-derived CAR-NK (CAR-iNK) cells could be used as a standardized and “off-the-shelf” product for cancer immunotherapy. In this review, we summarize the current status of the manufacturing techniques, genetic modification strategies, preclinical and clinical evidence of CAR-iNK cells, and discuss the challenges and future prospects of CAR-iNK cell therapy as a novel cellular immunotherapy in cancer. |
| Persistent Identifier | http://hdl.handle.net/10722/331439 |
| ISSN | 2021 Impact Factor: 7.419 2020 SCImago Journal Rankings: 1.323 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lin, Xiaotong | - |
| dc.contributor.author | Sun, Yao | - |
| dc.contributor.author | Dong, Xin | - |
| dc.contributor.author | Liu, Zishen | - |
| dc.contributor.author | Sugimura, Ryohichi | - |
| dc.contributor.author | Xie, Guozhu | - |
| dc.date.accessioned | 2023-09-21T06:55:45Z | - |
| dc.date.available | 2023-09-21T06:55:45Z | - |
| dc.date.issued | 2023-09-01 | - |
| dc.identifier.citation | Biomedicine and Pharmacotherapy, 2023, v. 165 | - |
| dc.identifier.issn | 0753-3322 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/331439 | - |
| dc.description.abstract | <p>Adoptive cell therapies (ACT) based on <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/chimeric-antigen-receptor" title="Learn more about chimeric antigen receptor from ScienceDirect's AI-generated Topic Pages">chimeric antigen receptor</a> (CAR)-modified <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/immunocompetent-cell" title="Learn more about immune cells from ScienceDirect's AI-generated Topic Pages">immune cells</a> have made great progress with six CAR-T cell products approved by the U.S. FDA for <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/hematologic-malignancy" title="Learn more about hematological malignancies from ScienceDirect's AI-generated Topic Pages">hematological malignancies</a>. Compared with CAR-T cells, CAR-NK cells have attracted increasing attention owing to their multiple killing mechanisms, higher safety profile, and broad sources. <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/induced-pluripotent-stem-cell" title="Learn more about Induced pluripotent stem cell from ScienceDirect's AI-generated Topic Pages">Induced pluripotent stem cell</a> (iPSC)-derived NK (iPSC-NK) cells possess a mature phenotype and potent cytolytic activity, and can provide a homogeneous population of CAR-NK cells that can be expanded to clinical scale. Thus, iPSC-derived CAR-NK (CAR-iNK) cells could be used as a standardized and “off-the-shelf” product for cancer <a href="https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/immunotherapy" title="Learn more about immunotherapy from ScienceDirect's AI-generated Topic Pages">immunotherapy</a>. In this review, we summarize the current status of the manufacturing techniques, genetic modification strategies, preclinical and clinical evidence of CAR-iNK cells, and discuss the challenges and future prospects of CAR-iNK cell therapy as a novel cellular immunotherapy in cancer.<span> </span></p> | - |
| dc.language | eng | - |
| dc.publisher | Elsevier | - |
| dc.relation.ispartof | Biomedicine and Pharmacotherapy | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | Chimeric antigen receptor | - |
| dc.subject | Immunotherpy | - |
| dc.subject | Induced pluripotent stem cell | - |
| dc.subject | Natural killer cell | - |
| dc.title | IPSC-derived CAR-NK cells for cancer immunotherapy | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.1016/j.biopha.2023.115123 | - |
| dc.identifier.scopus | eid_2-s2.0-85164355898 | - |
| dc.identifier.volume | 165 | - |
| dc.identifier.isi | WOS:001029051100001 | - |
| dc.identifier.issnl | 0753-3322 | - |